News

AddToAny

Google+ Facebook Twitter Twitter

Brain cancer liquid biopsy

Early detection of brain cancer has moved one step closer, according to new research.

New testing technology – the Dxcover Liquid Biopsy – has been shown to be effective even in the earlier days of cancer growth, at a smaller volume and lower stage.

Matt Baker, one of the scientists behind the test, said: “This breakthrough is a watershed moment in the development of early cancer detection. The study demonstrates the effectiveness of our Dxcover Brain Cancer Liquid Biopsy at detecting even the smallest brain tumours, which is great news for the care of future brain cancer patients.”

The study involved 177 patients with varying sizes of brain tumours providing blood samples for analysis by Dxcover.

The samples underwent the spectroscopic analysis under infra-red light and were processed using machine learning software. The test and analysis were found to be effective in identifying brain tumours in patients with gliomas as small as 0.2 cm3.

Dxcover Limited has raised £5.1m in funding to develop its spectroscopy and artificial intelligence technology as a Multi Cancer Early Detection (MCED) Platform.

bit.ly/3yCXS6w

Image credit | DXcover

Related Articles

IBMS research grants 2021

The five recipients of the IBMS research grants in 2021 introduce us to their research projectsnand discuss what impact their work could have.
 

Tech news: December

This month's top tech news stories

Blood marker for peripheral artery disease

Researchers at Washington University School of Medicine have shown that high levels of a specific protein circulating in the blood are an accurate marker for a severe type of peripheral artery disease that narrows the arteries in the legs and can raise the risk of heart attack.

Under the microscope: HeLa cells

In November's Under the Microscope, we focus on the HeLa cell line.

Top